Search Results - "Matthews, V."

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection by Phetsouphanh, Chansavath, Darley, David R., Wilson, Daniel B., Howe, Annett, Munier, C. Mee Ling, Patel, Sheila K., Juno, Jennifer A., Burrell, Louise M., Kent, Stephen J., Dore, Gregory J., Kelleher, Anthony D., Matthews, Gail V.

“…A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than…”
Get full text

National trends in retreatment of HCV due to reinfection or treatment failure in Australia by Carson, Joanne M., Barbieri, Sebastiano, Matthews, Gail V., Dore, Gregory J., Hajarizadeh, Behzad

“…Population-level uptake of direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection, including retreatment, can be estimated through…”
Get full text

Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase by Matthews, V. B, Åström, M.-B, Chan, M. H. S, Bruce, C. R, Krabbe, K. S, Prelovsek, O, Åkerström, T, Yfanti, C, Broholm, C, Mortensen, O. H, Penkowa, M, Hojman, P, Zankari, A, Watt, M. J, Bruunsgaard, H, Pedersen, B. K, Febbraio, M. A

“…Aims/hypothesis Brain-derived neurotrophic factor (BDNF) is produced in skeletal muscle, but its functional significance is unknown. We aimed to determine the…”
Get full text

Management of acute HCV infection in the era of direct-acting antiviral therapy by Martinello, Marianne, Hajarizadeh, Behzad, Grebely, Jason, Dore, Gregory J., Matthews, Gail V.

“…The management of acute HCV infection has not been standardized following the availability of direct-acting antiviral agents (DAAs) for chronic HCV infection,…”
Get full text

Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance by Matthews, V. B, Allen, T. L, Risis, S, Chan, M. H. S, Henstridge, D. C, Watson, N, Zaffino, L. A, Babb, J. R, Boon, J, Meikle, P. J, Jowett, J. B, Watt, M. J, Jansson, J.-O, Bruce, C. R, Febbraio, M. A

“…Aims/hypothesis The role of IL-6 in the development of obesity and hepatic insulin resistance is unclear and still the subject of controversy. We aimed to…”
Get full text

How I manage severe bacterial infections in people who inject drugs by Stewardson, Andrew J, Davis, Joshua S, Dunlop, Adrian J, Tong, Steven Y C, Matthews, Gail V

“…Injecting drug use is a risk factor for severe bacterial infection, but there is limited high-quality evidence to guide clinicians providing care to people who…”
Get more information

Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia by Hajarizadeh, B., Grebely, J., Matthews, G. V., Martinello, M., Dore, G. J.

“…Summary A government‐funded interferon‐free direct‐acting antiviral (DAA) treatment programme for chronic hepatitis C virus (HCV) infection has been available…”
Get full text

Persistent symptoms up to four months after community and hospital‐managed SARS‐CoV‐2 infection by Darley, David R, Dore, Gregory J, Cysique, Lucette, Wilhelm, Kay A, Andresen, David, Tonga, Katrina, Stone, Emily, Byrne, Anthony, Plit, Marshall, Masters, Jeffrey, Tang, Helen, Brew, Bruce, Cunningham, Philip, Kelleher, Anthony, Matthews, Gail V

Get full text

Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements by Grebely, Jason, Matthews, Gail V., Lloyd, Andrew R., Dore, Gregory J.

“…The demonstration that antiretroviral treatment is effective for the prevention of human immunodeficiency virus (HIV) transmission has important implications…”
Get full text

Rationale and methods for a cross-sectional study of mental health and wellbeing following river flooding in rural Australia, using a community-academic partnership approach by Longman, J M, Bennett-Levy, J, Matthews, V, Berry, H L, Passey, M E, Rolfe, M, Morgan, G G, Braddon, M, Bailie, R

“…Climate change is associated with greater frequency, duration, intensity and unpredictability of certain weather-related events, including floods. Floods harm…”
Get full text

One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review by Acheson, Liam S., Siefried, Krista J., Clifford, Brendan, Murray, Emily, Steele, Maureen, Clague, Liesa, Malone, Victoria, Roberts, Darren M., Ferguson, Lisa-Jayne, Matthews, Gail V., Ezard, Nadine

“…•33% of Staphylococcus aureus bacteraemia (SAB) cases were among people who inject drugs (PWID).•One-third of PWID with SAB were discharged within 14 days,…”
Get full text

Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral—Based Therapy by Taylor, Lynn E., Swan, Tracy, Matthews, Gail V.

“…Where active antiretroviral therapy (ART) is accessible, human immunodeficiency virus (HIV) is a survivable illness and effective ART can reduce HIV…”
Get full text

Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection by Phetsouphanh, Chansavath, Jacka, Brendan, Ballouz, Sara, Jackson, Katherine J. L., Wilson, Daniel B., Manandhar, Bikash, Klemm, Vera, Tan, Hyon-Xhi, Wheatley, Adam, Aggarwal, Anupriya, Akerman, Anouschka, Milogiannakis, Vanessa, Starr, Mitchell, Cunningham, Phillip, Turville, Stuart G., Kent, Stephen J., Byrne, Anthony, Brew, Bruce J., Darley, David R., Dore, Gregory J., Kelleher, Anthony D., Matthews, Gail V.

“…This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID…”
Get full text

HCV reinfection incidence among individuals treated for recent infection by Martinello, M., Grebely, J., Petoumenos, K., Gane, E., Hellard, M., Shaw, D., Sasadeusz, J., Applegate, T. L., Dore, G. J., Matthews, G. V.

“…Summary One challenge to HCV elimination through therapeutic intervention is reinfection. The aim of this analysis was to calculate the incidence of HCV…”
Get full text

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial by Rockstroh, Jürgen K, Prof, Nelson, Mark, MD, Katlama, Christine, Prof, Lalezari, Jay, MD, Mallolas, Josep, MD, Bloch, Mark, MBBS, Matthews, Gail V, Prof, Saag, Michael S, Prof, Zamor, Philippe J, MD, Orkin, Chloe, MBChB, Gress, Jacqueline, BA, Klopfer, Stephanie, PhD, Shaughnessy, Melissa, MS, Wahl, Janice, MD, Nguyen, Bach-Yen T, MD, Barr, Eliav, MD, Platt, Heather L, MD, Robertson, Michael N, MD, Sulkowski, Mark, Prof

“…Summary Background Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in patients with HIV-1. The C-EDGE CO-INFECTION study…”
Get full text

Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C by Matthews, G. V., Pham, S. T., Hellard, M., Grebely, J., Zhang, L., Oon, A., Marks, P., van Beek, I., Rawlinson, W., Kaldor, J. M., Lloyd, A., Dore, G. J., White, P. A.

“…Background. Injecting drug users remain the population at greatest risk of acquiring hepatitis C virus (HCV) infection, although a recent increase in case of…”
Get full text

Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia by Dharan, Nila J, Sasson, Sarah C, Ahlenstiel, Golo, Andersen, Christopher R, Bloch, Mark, Buckland, Griselda, Hamad, Nada, Han, Win Min, Kelleher, Anthony D, Long, Georgina V, Matthews, Gail V, Mina, Michael M, Papot, Emmanuelle, Petoumenos, Kathy, Swaminathan, Sanjay, Withers, Barbara, Yun, James, Polizzotto, Mark N

“…People with immunocompromising conditions are at increased risk of SARS-CoV-2 infection and mortality, however early in the pandemic it was challenging to…”
Get full text

Abnormal left atrial body stiffness is predicted by appendage size: impact of appendage occlusion on left atrial mechanics assessed by pressure-volume analysis by Bregasi, Alda, Freeman, James V, Curtis, Jeptha P, Akar, Joseph G, Ortiz-Leon, Xochitl A, Maia, Julia H, Higgins, Angela Y, Matthews, Ray V, Sinusas, Albert J, McNamara, Robert L, Sugeng, Lissa, Lin, Ben A

“…Atrial cardiomyopathy has been recognized as having important consequences for cardiac performance and clinical outcomes. The pathophysiological role of the…”
Get more information

The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis by Lamoury, François M J, Jacka, Brendan, Bartlett, Sofia, Bull, Rowena A, Wong, Arthur, Amin, Janaki, Schinkel, Janke, Poon, Art F, Matthews, Gail V, Grebely, Jason, Dore, Gregory J, Applegate, Tanya L

“…Sequencing is important for understanding the molecular epidemiology and viral evolution of hepatitis C virus (HCV) infection. To date, there is little…”
Get full text

Characteristics and Treatment Outcomes among HIV-Infected Individuals in the Australian Trial in Acute Hepatitis C by Matthews, G. V., Hellard, M., Haber, P., Yeung, B., Marks, P., Baker, D., McCaughan, G., Sasadeusz, J., White, P., Rawlinson, W., Lloyd, A., Kaldor, J., Dore, G. J.

“…Background. The Australian Trial in Acute Hepatitis C (ATAHC) is a National Institutes of Health-funded prospective cohort study of the natural history and…”
Get full text